Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia
复制标题
DOI：
10.1182/blood-2006-04-017400
复制
发表时间：
2006-10-15
期刊：
影响因子：
20.3
通讯作者：
Cortes, Jorge
中科院分区：
文献类型：
--
作者：
Kovitz, Craig;Kantarjian, Hagop;Cortes, Jorge
在伊马替尼治疗期间，一些慢性髓性白血病（CML）患者在费城染色体（Ph）阴性细胞中出现染色体异常。这些异常通常是短暂的，其临床后果尚不清楚。虽然一些报告表明，异常可能与继发性骨髓增生异常综合征（MDS），诊断并不总是建立使用标准标准。我们报告3例患者伊马替尼治疗慢性粒细胞白血病谁随后被发现有染色体异常的Ph阴性细胞。其中1例发生急性髓细胞性白血病（AML），另2例发生高危MDS，并迅速转化为AML。这些病例是在总共1701例患者的研究组中确定的。虽然这些事件是罕见的，但研究结果强调需要密切监测伊马替尼治疗的CML患者。
During therapy with imatinib, some patients with chronic myeloid leukemia (CML) develop chromosomal abnormalities in Philadelphia chromosome (Ph)-negative cells. These abnormalities are frequently transient and their clinical consequence is unclear. Although some reports have suggested that the abnormalities might be associated with secondary myelodysplastic syndrome (MDS), the diagnosis has not always been established using standard criteria. We report 3 cases of patients treated with imatinib for CML who were subsequently found to have chromosomal abnormalities in Ph-negative cells. One of them developed acute myelogenous leukemia (AML) and the other 2 developed high-risk MDS that rapidly transformed to AML. These cases were identified in a total study group of 1701 patients. Although these occurrences are rare, the findings highlight the need for close monitoring of patients with CML treated with imatinib.